



The IGBA CEO Advisory Committee: Patient Access, Industry Value, and Global Cooperation in a Reshaping World

London, December 3, 2025

On 20 November, the [CEO Advisory Committee of the International Generic and Biosimilar Medicines Association \(IGBA\)](#) convened to discuss how the generics and biosimilars sector can continue to deliver on its mission—ensuring affordable, safe, effective and quality-assured therapies for patients— in a shifting international landscape.

The Committee’s discussion highlighted how uninterrupted patient access to quality-assured medicines is essential to achieving well-being for all.

Generics and biosimilars make care scalable, sustainable, and inclusive, and are an invaluable asset in addressing acute healthcare crises, combating non-communicable diseases, financial hardship connected to increased cost of healthcare, and alleviating the impacts of an ageing population.

The critical role of generic and biosimilar medicines in advancing health outcomes, strengthening economic performance, and ensuring resilient healthcare systems worldwide was emphasized. The message to governments, health ministries, regulators, payers and civil society is clear: healthcare policies that recognize the value of generic and biosimilar medicines as a cornerstone of patient care are critical to supporting access to medicines.

Access, though, depends on resilient, diversified supply chains; the full realization of the social and economic value of generic and biosimilar medicines; regulatory harmonization that enables more efficient development; public trust in the robustness of generic and biosimilar medicines’ regulatory standards; and balanced intellectual property systems, among others. These elements are fundamental to safeguarding the continuity of care and enabling patient access to quality-assured therapies.

The Committee discussed how to articulate the collective value of the industry: emphasizing that generics and biosimilars account for the majority of prescription medicines dispensed worldwide, enabling earlier treatment, and billions in savings for reinvestment. Members also explored how to position industry for the future, particularly in a time of political and policy uncertainty: by highlighting investments and developing partnerships that strengthen supply security and global patient access. Additionally, the Committee underscored the need to advocate predictable, cooperative policies that

ensure a resilient, sustainable ecosystem.

A Call to Action

The CEO Advisory Committee urges policymakers to recognize the strategic importance of generic and biosimilar medicines within national and global health strategies. Supporting a competitive and sustainable health ecosystem, where generics and biosimilars are recognized as a fundamental pillar for well-being, social, and economic prosperity, will be vital to ensuring equitable access, economic resilience, and preparedness for the challenges ahead.